SCHEMBL7031901

SCHEMBL7031901

O=C[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NS(=O)(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.54
MMP9 P14780 7/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
ADAMTS4 O75173 1/20 0.51
CTSL P07711 2/20 0.48
CTSS P25774 2/20 0.48
CTSK P43235 2/20 0.48
CTSB P07858 3/20 0.47
ADAMTS5 Q9UNA0 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP13 P45452 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7031900 1.00 MMP2 (0.54) MMP2MMP9MEN1KMT2AL3MBTL1
SCHEMBL7026771 0.89 CTSS (0.60) MMP2MMP9MEN1KMT2AL3MBTL1
SCHEMBL7026768 0.89 CTSS (0.60) MMP2MMP9MEN1KMT2AL3MBTL1
SCHEMBL7025291 0.85 ALDH1A1 (0.55) MMP2MMP9ADAMTS4CTSLCTSS
SCHEMBL7025286 0.85 ALDH1A1 (0.55) MMP2MMP9ADAMTS4CTSLCTSS
SCHEMBL7103944 0.85 ALDH1A1 (0.55) MMP2MMP9ADAMTS4CTSLCTSS
SCHEMBL16334319 0.83 CTSB (0.53) MMP9CTSLCTSSCTSB
SCHEMBL8912956 0.80 L3MBTL1 (0.78) MMP2MMP9MEN1KMT2AL3MBTL1
SCHEMBL7028199 0.78 CTSL (0.65) CTSLCTSSCTSB
SCHEMBL14513407 0.78 CTSL (0.65) CTSLCTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002048097-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INT INC (US) 2003-05-08 WO claimed
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections DENDREON CORPORATION 2002-08-08 US claimed
WO-2002048097-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INTERNATIONAL, INC. (US) 2002-06-20 WO claimed
WO-2002048097-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INT INC (US) 2003-05-08 WO disclosed
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections DENDREON CORPORATION 2002-08-08 US disclosed
WO-2002048097-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INTERNATIONAL, INC. (US) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections CAT, CTSA, CTRL MMP2 25/4885MMP9 48/4885MEN1 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.